47
Participants
Start Date
October 31, 2013
Primary Completion Date
January 31, 2016
Study Completion Date
February 29, 2016
CC-292
375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
Placebo
Twice daily for 28 days
Joao Nascimento, MD, Bridgeport
NYU Langone Medical Center, New York
Altoona Center for Clinical Research, Duncansville
Columbia Medical Practice, Columbia
Mountain State Clinical Research, Clarksburg
DJL Clinical Research, Charlotte
Med Univ of South Carolina, Charleston
PMG Research of Charlotte LLC, Rock Hill
Southeastern Integrated Medical, Gainesville
Integral Rheumatology and Immunology specialists, Plantation
Family Arthritis Center, Jupiter
Ocala Rheumatology Research Center, Ocala
Achieve Clinical Research LLC, Birmingham
Ramesh C Gupta MD, Memphis
West Tennessee Research Institute, Jackson
Borgess Research Institute, Kalamazoo
Gundersen Clinic Ltd, Onalaska
Generations Medical Research, Hot Springs
Lynn Health Science Instiute, Oklahoma City
DM Clinical Research, Houston
Austin Regional Clinic, Austin
Arizona Arthritis and Rheumatology Research, PLLC, Phoenix
Albuquerque Clinic, Albuquerque
UCLA, Los Angeles
Clinical Pharmacology Study Group, Worcester
Arthritis and Osteoporosis Associates, Freehold
Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee
Lead Sponsor
Celgene
INDUSTRY